Milhem, M., Zakharia, Y., Davar, D., Buchbinder, E., Medina, T., Daud, A., Ribas, A., Niu, J., Gibney, G., Margolin, K., Olszanski, A., Mehmi, I., Sato, T., Shaheen, M., Morris, A., Mauro, D., Campbell, K., Kelley, H., Bao, R., Weiner, G., Luke, J., Krieg, A., Wooldridge, J., & Kirkwood, J. (n.d.). 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma. Journal for immunotherapy of cancer, 8, A331. http://access.bl.uk/ark:/81055/vdc_100144710968.0x000005